An Open-label, Phase 1/2, Dose-escalation and Expansion Study of SBT6050 Combined With Other HER2-directed Therapies in Subjects With Pretreated Unresectable Locally Advanced and/or Metastatic HER2-expressing or HER2-amplified Cancers
Latest Information Update: 22 Aug 2022
At a glance
- Drugs Capecitabine (Primary) ; Pertuzumab zuvotolimod (Primary) ; Trastuzumab (Primary) ; Trastuzumab-deruxtecan (Primary) ; Tucatinib (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Silverback Therapeutics
- 22 Jul 2022 Status changed from active, no longer recruiting to discontinued.
- 04 Apr 2022 Planned End Date changed from 1 Dec 2025 to 1 Apr 2023.
- 04 Apr 2022 Planned primary completion date changed from 1 Dec 2023 to 1 Apr 2023.